

Malgorzata Kluba has been a Senior Biotechnology Analyst at Candriam since 2019.
Malgorzata holds PhD degree in biochemistry and biotechnology from University of Leuven, Belgium, where she had been working on cancer signaling pathways. Before joining Candriam Malgorzata spent 4 years as an R&D scientist at ActoBio Therapeutics (Intrexon Actobiotics) in Belgium – a synthetic biology company where she had been working on novel drug delivery platform. Before that she worked as a journalist for a life sciences communication agency (BioVox / Tunstone Communications) focusing on Belgian biotechnology market.
Discover the latest articles by Malgorzata Kluba

Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities
And we would rather not have to go through this – which would mean we won the battle and cancer is curable.

Highlighted, Malgorzata Kluba, Oncology, Outlook 2022
Taking a careful aim at cancers?
Oncology has seen some remarkable advances over the past few decades